494 related articles for article (PubMed ID: 31130676)
1. Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Takahashi T; Tateishi A; Bychkov A; Fukuoka J
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130676
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
5. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP
JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721
[TBL] [Abstract][Full Text] [Related]
6. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
7. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
8. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
Rihawi K; Gelsomino F; Sperandi F; Melotti B; Fiorentino M; Casolari L; Ardizzoni A
Ther Adv Respir Dis; 2017 Sep; 11(9):353-373. PubMed ID: 28818019
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
11. What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
Bravaccini S
Lung Cancer; 2019 Jun; 132():152-153. PubMed ID: 30879776
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
Qin Q; Li B
J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226
[TBL] [Abstract][Full Text] [Related]
16. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
17. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Lin M; Luo H; Liang S; Chen J; Liu A; Niu L; Jiang Y
J Clin Invest; 2020 May; 130(5):2560-2569. PubMed ID: 32027620
[TBL] [Abstract][Full Text] [Related]
19. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
